SynAct Pharma AB

SYNACT

SE0008241491

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2025-06-13 pm EDT			5-day change	1st Jan Change
16.82 ^SEK	-0.94%		-10.15%	+87.62%

Jun. 11	Finserve Micro Cap rose 4.74 percent in May – improved risk appetite among investors	FW
Jun. 04	SynAct Pharma AB - Analyst/Investor Day

Synact Gets Patent Term Adjustment for Resomelagon Therapy

Published on 05/12/2025 at 08:43

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about SynAct Pharma AB

Finserve Micro Cap rose 4.74 percent in May – improved risk appetite among investors	Jun. 11	FW
SynAct Pharma AB - Analyst/Investor Day	Jun. 04
Stockholm Bullets - Project commitments surge after bid from Sweco (R)	Jun. 04	FW
The mood is cheerful on the Stockholm Stock Exchange, with the OMXS30 index up 0.8 percent.	Jun. 04	FW
Synact Pharma is focusing on two parallel development tracks for resomelagon	Jun. 04	FW
SynAct Pharma AB Refines Development Strategy for Lead Compound Resomelagon	Jun. 04	CI
Stockholm Bullets - Project commitments surge after bid from Sweco	Jun. 04	FW
Synact Pharma Shares In Directed Issue At Subscription Price Of SEK 16 Per Share	Jun. 04	RE
Synact Pharma is carrying out a directed new share issue of SEK 37 million.	Jun. 04	FW
SynAct Pharma Takes Out Credit Facility Of SEK 30 Million	Jun. 04	RE
Synact Pharma takes out a credit facility of SEK 30 million	Jun. 04	FW
SynAct Pharma AB Takes Out A Credit Facility of SEK 30 Million That Extends the Company's Financial Runway to Mid-2026, Which Strongly Strengthens Partnership Opportunities	Jun. 03	CI
Redeye lowers fair value for Synact Pharma to SEK 21 (22)	May. 28	FW
SynAct Pharma AB Elects Jeppe Ragnar Andersen as Members of the Board of Directors	May. 27	CI
Synact Pharma increases loss, 'main focus on recruiting patients before the end of 2025' - CEO (update)	May. 27	FW
Synact Pharma increases loss, 'main focus on recruiting patients before the end of 2025' - CEO	May. 27	FW
SynAct Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 27	CI
SynAct Receives Issue Notification and Patent Term Adjustment for US Patent Covering Resomelagon Combination Therapy	May. 12	CI
Synact Pharma gets US patent extended by two years	May. 12	FW
Synact Gets Patent Term Adjustment for Resomelagon Therapy	May. 12	RE
SynAct Pharma Secures Patent for Resomelagon in Combination with MTX	Apr. 23	CI
Synact Pharma on track for patent approval in the US for combination therapy with resomel agon	Apr. 23	FW
SynAct Receives Notice Of Allowance For Grant Of U.S. Patent	Apr. 23	RE
SynAct Pharma AB Receives Notice of Allowance for Grant of US Patent Covering Resomelagon Combination Therapy	Apr. 23	CI
Synact Pharma starts Phase 2 study with resomelagon in Brazil for dengue fever	Apr. 11	FW

SynAct Pharma AB is a manufacturer of biological products. The Company is located in Lund, Sweden. It develops medicines for acute impairment in inflammatory diseases. The company's drug candidate AP1189 is intended for the treatment of arthritis including psoriasis arthritis.

Employees

Sector

Biotechnology & Medical Research

Calendar

Aug. 19 - Q2 2025 Earnings Release

More about the company